Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02657304
Other study ID # 1508146
Secondary ID 2015-A01635-44
Status Completed
Phase N/A
First received
Last updated
Start date March 21, 2016
Est. completion date January 12, 2021

Study information

Verified date August 2021
Source Centre Hospitalier Universitaire de Saint Etienne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sleep apnea (SA) affects more than 4% from general population and is largely underdiagnosed. SA can increase the occurrence of cardiovascular, endocrine and metabolic events (particularly stroke, diabetes & obesity). CPAP is currently the Gold Standard treatment of SA and to prevent these events, with a major clinical benefit, long term adherence to CPAP is a significant problem where a significant rate of rejection and abundance after 6 months of treatment.


Description:

Sleep apnea (SA) affects more than 4% from general population (20% of people over 65 years) and is largely underdiagnosed, it can be rise up by some factors such as: obesity, male gender. Sleep Apnea can increase the occurrence of cardiovascular, endocrine and metabolic events (particularly stroke, diabetes & obesity). CPAP is currently the Gold Standard treatment of SA and to prevent these events, with a major clinical benefit, long term adherence to CPAP is a significant problem where a significant rate of rejection and abundance after 6 months of treatment. The investigators hypothesize that an early education and information of SA (in the first 2 weeks after diagnosis of SA and one telephonic call/month while 5 months) would allow to increase significantly the optimal observance of CPAP (> 5 h/night). Thus, in this study, we will compare evolution of the observance of CPAP (h/night), of the apnea hypopnea index (AHI), patient knowledge of their SA and its deleterious health consequences in an early education and information during five months against a control group receiving only usual care (standard).


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date January 12, 2021
Est. primary completion date January 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients affiliated or entitled to a French medical insurance - Patients of both gender, aged from 18 to 80 years - Patients with AHI > 30/hour or between 15 & 30/h with Sleep Fragmentation Index (SFI) of more than 10/h - Signature of consent Exclusion Criteria: - Known diseases which contraindicated used of CPAP treatment

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Coaching group
patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
Other:
Control group
patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).

Locations

Country Name City State
France Chu Saint-Etienne St Etienne

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Saint Etienne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Observance Percentage of patients with a mean duration of observance of more than 5h/night after five months of follow-up in the coached and the control groups 5 months
See also
  Status Clinical Trial Phase
Completed NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study Phase 4
Active, not recruiting NCT00746928 - Cardiovascular Consequences of Intermittent Hypoxia in Healthy Subjects N/A
Terminated NCT00816829 - Effect of Fenofibrate on Sleep Apnea Syndrome Phase 2
Recruiting NCT00152711 - Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis N/A
Completed NCT02482480 - Comprehensive Management for the Treatment of Obstructive Sleep Apnea N/A
Recruiting NCT02408172 - Effects of Metoprolol and Amlodipine on Cardiac Remodeling, Arrhythmias and Blood Pressure Variation in Hypertensive Patients With Sleep Apnea Syndrome Phase 2/Phase 3
Terminated NCT01354756 - Validation of Apnea LinkTM for Sleep Apnea Syndrome Screening in a Bariatric Population N/A
Terminated NCT01196845 - Inflammation and Oxidative Stress of Adipose Tissue in Sleep Apnea Syndrome N/A
Completed NCT03116958 - MyOSA : Management and Treatment of Patients With Obstructive Sleep Apnea Syndrome(OSAS) Through a Telemedicine System N/A
Terminated NCT02649933 - Detection of Sleep Apnea Syndrome (OSA) in Pregnant Women and Assessment of Impact of OSA on Pregnancy Course N/A
Completed NCT02789696 - Prevalence of Acromegaly in a Diagnostic Consultation for Sleep Apnea Syndrome N/A
Completed NCT01164631 - Pharyngeal Size in Patients With Obstructive Tonsils Under Orthodontic Treatment Phase 4
Completed NCT00317083 - Cough Reflex and Obstructive Sleep Apnea Syndrome N/A
Completed NCT02893865 - Evolution of Oxidative Stress in Coronary Patients With Moderate Sleep Apnea Syndrome After Treatment With Continuous Positive Airway Pressure N/A
Completed NCT02234765 - Management of Patients With Suspected of Sleep Apnea-hypopnea Syndrome From Primary Care N/A
Completed NCT01752556 - Cost-effectiveness of Home Respiratory Polygraphy Phase 3
Completed NCT00001723 - Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases Phase 2
Completed NCT02148432 - Establishment of Ideal IV Sedative Regimen for Successful Fiberoptic Bronchoscopy in Assessing the Site, Severity of Sleep Apnea Syndrome N/A
Completed NCT02591979 - PASHOS Project: Advanced Platform for Sleep Apnea Syndrome Assessment
Recruiting NCT00936273 - Sleep Apnea and Periodic Breathing N/A